Embed Size (px)
Citation preview
5%Phase III
2%Phase VI
23%Preclinical
29%
Not in trials or preclinic
10%
September 4-7 2018, Boston, MA
What indication looks most promising for the next approval?
What is the most important aspect of the therapeutic development of CAR-TCR therapies?
What are your aspirations for the future of the CAR-TCR industry?
What is likely to be the best strategy to target solid tumor indications?
What is the biggest limitation of your current manufacturing strategy?
Alternative CAR Vehicles e.g. CAR-NK 18%
Incorporate switch/control mechanisms 23%
TCR Therapies 25%
61% Combination therapies
32% Improve targeting
of respondents believe multiple myeloma looks most promising for the
next CAR-TCR approval
%
Which development will have the biggest commercial impact?
41%
15%
10%
9%
8%
7%
What is the biggest challenge
in development of CAR-TCR
therapies right now?
In which region are you based?
25%Europe
5%Asia
2%Australia
62% North America
5% Global
1% South America
Multiple MyelomaLung Cancer
epithelialtumourtargeting Extentions
of B cellmalignancies
Mye
lom
a
Leukemia
BC
MA
Gliob
lastom
a
Other b
lood cell
ma
ligna
ncies
BC
MA
Hematologicalmaligancies
Hematologicalmaligancies
MyelomaAML
Adaptative Immunity
Mel
ano
ma
Melanoma
Myelom
a
B c
ell c
anc
ers
Solid
tum
or
Lymphoma Any solid tumors
Solid CancersMyxoid Lyposarcoma
Non-Hodgkin LymphomasMyxoid Lyposarcoma
Melanoma
Manufacturing CureAllogenic
Manufacturing
ProvideSpeed and precision
Fine-tuning the TCR
Earlyengagement withregulators
Gen
e ed
itin
g
Fine-tuningSpeed
tumour
antig
enselection
Safe
ty
Desig
n
PriceIden
tifi
cati
on
E�cacy
Patients
Therapies
Cost
Therapies
E�cacy
Targ
ets
Ca
ncers
A�
ord
ab
le
Firs
t Li
nePr
oduc
ts
Standardisation
Developing persistence
Fine
-tun
ing
the
TC
R
Trea
tmen
t
Solid Tumors
CAR TCR
Need
ControlReduced CRS Expansion
ManufactureCapabilities
Full SafetyConsiderations
42%Lack of
automation innovation
30%Cost of goods
9%Raw
materials
15%Logistics
9%Supply chain
What does the next
technology advancement
need to be?8%
Cryopreservation/freezing
technologies
10%Analytics
38%Manufacturing
automation
22%Gene editing technologies
28%Closed system manufacturing
21%Control/switch
mechanisms
14%Phase II
28%Phase I
Join 700+ leading CAR-T and TCR developersthis September at the 4th Annual CAR-TCR Summit – Changing Lives with CAR-T & TCR Cell Immunotherapies PRODUCED BY
September 4-7 2018, Boston, MA
Changing Lives with CAR-T & TCR Cell Immunotherapies
Tel: +1 212 537 5898 Email: [email protected] www.car-tcr-summit.com @CAR_TCell Cell Immunotherapy
Moments where we can come together with passionate individuals and companies who are focused on advancing cancer care are inspiring, and the CAR-TCR Summit is no different... Novartis
André ChoulikaCEOCellectis
James NobleCEOAdaptimmune
Philip GregoryCSObluebird bio
Carl June Professor & Director Translational Research, Abramson Cancer Center University of Pennsylvania
David ChangCEOAllogene Therapeutics
Usman AzamPresident & CEOTmunity
Expert speakers include:
Lead Partner
700+ Attendees300+ Organisations
90+ Expert Speakers1 Comprehensive CAR-TCR Showcase
Expertise Partner
DOWNLOAD THE BROCHURE
Tel: +1 212 537 5898 Email: [email protected] @CAR_TCell Cell Immunotherapy
www.car-tcr-summit.com
77%23%
88% of those that responded allogeneic were from the Asia-Pacific geographic region
Solid tumor efficacy Pricing and reimbursement Cost of goods Global delivery of therapy to patients
Safety and adverse events Other Viral vector engineering
Allogeneic Therapies Autologous Therapies
How soon is your company set to file for regulatory approval for any products in your pipeline
What phase of development are you in?
16%
3%
29%
18%15%
13%
8%
7%
What company type do you belong to?
Small/medium biotech CMO Start up biotech Academic research institute/hospital
Solution/service provider Large pharma Other CRO
40%0-2 years
32%3-5 years
9%5-9 years
4%10+ years
15%Longer
